-
Xi's 'blunt' warning to Trump on Taiwan exposes profound risks: analysts
-
Blackouts and protests as Cuba says fuel has 'run out'
-
Germany's Jaeger takes early PGA lead as McIlroy opens with bogey
-
Sinner reaches Italian Open semis, breaks Masters 1000 winning streak record
-
Germany's Merz calls for more investment, less subsidies in EU budget
-
UK minister quits ahead of possible challenge to Starmer
-
Latvia prime minister resigns over straying Ukraine drones
-
Stocks diverge tracking tech, US-China talks
-
Afghanistan's water crisis worsened last year: UN report
-
Russia pummels Kyiv, killing five and denting peace hopes
-
Stars flying into Cannes in private jets 'obscene', say ex-pilots
-
McIlroy eyeing early charge as PGA Championship begins
-
Arteta seeks goal spree for Premier League title cushion
-
UK PM in peril as potential successors jockey for position
-
US jury awards $49.5 mn damages to Boeing 737 MAX victim's family
-
South Africa court clears way for Zuma's arms graft trial
-
Nobel winner Mukwege warns of predatory US deal for DR Congo
-
UK economy resilient as Mideast war, political risks loom
-
Russia pummels Kyiv, killing three and denting peace hopes
-
Subdued Trump left waiting for 'big hug' from Xi
-
Slot has 'every reason to believe' he will remain as Liverpool boss
-
British PM battles to stay in power amid rebellion
-
Ex-Philippine drug war enforcer flees Senate refuge
-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
D.Johnson--AT